You can find more information about plasmepsin II using the following links:

PFID

PFID Old

Formal Annotation

PlasmoDB

TDR Targets

Subcellular Localization

Affecting Drugs

Drug Name

PubMed Articles (year of publication)

PF3D7_1408000

PF14_0077

plasmepsin II

PlasmoDB

TDR

(2R,3R,4R)-2-Benzyloxy-3,4-dihydroxy-N-[(1S,2R)- 2-hydroxyindan-1-yl]-4-[(2R)-3-oxo-1-oxa-4-aza-cyclotridec-2-yl]-butyramide	Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV
(2s,3s)-3-amino-2-hydroxy-4-phenylbutyric acid in	Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases
(4R)-3-[(2S,3S)-3-[[(2R)-2-[[2-(4-aminophenyl)acetyl]amino]-3-methylsulfanylpropanoyl]amino]-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide	Deciphering the mechanism of potent peptidomimetic inhibitors targeting plasmepsins - biochemical and structural insights
(4R)-N-tert-Butyl-3-[(2S,3S)-2-hydroxy-3-({N-[(isoquinolin-5-yloxy)acetyl]-S-methyl-L-cysteinyl}amino)-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide	High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor
(5s,6r)-3-aza-3-benzyl-5-hydroxy-7-phenyl-6- [(picolyl-l-valinyl)amino]-heptanoyl amide	Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II
(6aR, 12aS)-12a-Hydroxy-9-methoxy-2,3-dimethylenedioxy-8-prenylrotenone	Virtual Screening Techniques to Probe the Antimalarial Activity of some Traditionally Used Phytochemicals
(S)-2-((4-chlorophenyl)((1-((2,5-dichlorophenyl)sulfonyl)piperidin-4-yl)oxy)methyl)pyridine	Hydroxyethylamine Based Phthalimides as New Class of Plasmepsin Hits: Design, Synthesis and Antimalarial Evaluation
(S)-N-((2R,3S)-4-(4-(4-Fluorobenzyl)piperazin-1-yl)-3-hydroxy-1-phenylbutan-2-yl)-2-(1,3-dioxoisoindolin-2-yl)-3-phenylpropanamide.	Hydroxyethylamine Based Phthalimides as New Class of Plasmepsin Hits: Design, Synthesis and Antimalarial Evaluation
[amino({5-phenyl-3-[(E)-2-phenylethenyl]- 4,5-dihydro-1H-pyrazol-1-yl})methylidene]azanium	Successful application of virtual screening and molecular dynamics simulations against antimalarial molecular targets
1-(4-amidinophenyl)-3-(4-phenoxyphenyl)urea	New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins
1-(4-phenylphenyl)-2[2-(pyridinyl-2-yl)-1,3-benzdiazol-1-yl]ethanone	New benzimidazole derivatives as antiplasmodial agents and plasmepsin inhibitors: synthesis and analysis of structure-activity relationships
1,2-dihydroxyethylene	Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations
1,2-dihydroxyethylene based compounds	Discovery of non-peptide inhibitors of Plasmepsin II by structure-based virtual screening
1,2-diphenylhydrazine	Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors
1,2-dipyridinylhydrazine	Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors
1,3,4-oxadiazole	Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations
1-[2-methoxy-5-[(1E)-3-phenylbuta-1,3-dienyl]phenyl]sulfonylpyridine	Antimalarial activity of 4-metoxychalcones: docking studies as falcipain/plasmepsin inhibitors, ADMET and lipophilic efficiency analysis to identify a putative oral lead candidate
1-[2-methoxy-5-[(1E)-3-phenylbuta-1,3-dienyl]phenyl]sulfonylpyrrolidine	Antimalarial activity of 4-metoxychalcones: docking studies as falcipain/plasmepsin inhibitors, ADMET and lipophilic efficiency analysis to identify a putative oral lead candidate
11-azatricyclo[6.2.1.02,7]undeca-2(7),3,5-triene tricycle	De Novo design, synthesis, and in vitro evaluation of a new class of nonpeptidic inhibitors of the malarial enzyme plasmepsin II
13- and 16-membred macrocycles	Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV
2,2-diphenyl acetohydrazide	Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors
2,3,4,7-tetrahydro-1h-azepine	Computer-aided design and synthesis of nonpeptidic plasmepsin II and IV inhibitors
2-Amino-3-(((2S,5R)-5-isopropyltetrahydrofuran-2-yl)methyl)-7- phenylquinazolin-4(3H)-one	Fragment-Based Discovery of 2-Aminoquinazolin-4(3H)-ones As Novel Class Nonpeptidomimetic Inhibitors of the Plasmepsins I, II, and IV
2-Amino-7-(4-phenethylbenzyl)-3-((tetrahydrofuran-2-yl)methyl)quinazolin-4(3H)-one	Exploring Aspartic Protease Inhibitor Binding to Design-Selective Antimalarials
2-Amino-7-phenyl-3-(((2R,5S)-5-phenyltetrahydrofuran-2-yl)methyl)quinazolin- 4(3H)-one	Fragment-Based Discovery of 2-Aminoquinazolin-4(3H)-ones As Novel Class Nonpeptidomimetic Inhibitors of the Plasmepsins I, II, and IV
2-Amino-7-phenyl-3-(((2S,5R)-5-phenyltetrahydrofuran-2- yl)methyl)quinazolin-4(3H)-one	Fragment-Based Discovery of 2-Aminoquinazolin-4(3H)-ones As Novel Class Nonpeptidomimetic Inhibitors of the Plasmepsins I, II, and IV
2-methoxy benzohydrazide	Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors
2-nitro benzohydrazide	Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors
2-tert-Butyloxycarbonylamino-7-benzyloxy-4- oxaheptanoic acid	[Selective inhibitors of plasmepsin II from Plasmodium falciparum based on pepstatin]
3-(7-(4-(4l3-butyl)phenyl)-2-amino-4-oxo-3-((tetrahydrofuran-2-yl)methyl)-3,4-dihydroquinazolin-5-yl)propanoic acid	2-Aminoquinazolin-4(3H)-one based plasmepsin inhibitors with improved hydrophilicity and selectivity
4(s)-amino-3(s)-hydroxy-5-phenylpentanoic acid	Molecular dynamics simulations of the three dimensional model of plasmepsin II-peptidic inhibitor complexes
4-[2-methoxy-5-[(1E)-3-phenylbuta-1,3-dienyl]phenyl]sulfonylmorpholine	Antimalarial activity of 4-metoxychalcones: docking studies as falcipain/plasmepsin inhibitors, ADMET and lipophilic efficiency analysis to identify a putative oral lead candidate
4-aminopiperidine	Achiral, cheap, and potent inhibitors of Plasmepsins I, II, and IV
7,8-dihydroxy-3-(4-nitrobenzoyl)-2-(4-nitrophenyl)chromen-4-one	Antimalarial activity of HIV-1 protease inhibitor in chromone series
7-azabicyclo[2.2.1]heptane	Potent inhibitors of malarial aspartic proteases, the plasmepsins, by hydroformylation of substituted 7-azanorbornenes
Acridinyl hydrazides	Identification of acridinyl hydrazides as potent aspartic protease inhibitors
Acylals	Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents
Albitiazolium	Antimalarial activity of HIV-1 protease inhibitor in chromone series
Alkoxyurea	Dietary flavonoids fisetin and myricetin: dual inhibitors of Plasmodium falciparum falcipain-2 and plasmepsin II
Alln	Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors
Allophenylnorstatine	Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target Search for substrate-based inhibitors fitting the S2' space of malarial aspartic protease plasmepsin II Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II
Allophenylnorstatine	Discovery of non-peptide inhibitors of Plasmepsin II by structure-based virtual screening
Allophenylnorstatine wapns	Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases
AMD3100	Plerixafor and related macrocyclic amines are potential drug candidates in treatment of malaria by "filling the flap" region of plasmepsin enzymes
Amides	Design and discovery of plasmepsin II inhibitors using an automated workflow on large-scale grids
Aminohydantoin	Evaluation of aminohydantoins as a novel class of antimalarial agents
aminopiperidine	Discovery of non-peptide inhibitors of Plasmepsin II by structure-based virtual screening
Artemisinin	Artemisinin-dipeptidyl vinyl sulfone hybrid molecules: design, synthesis and preliminary SAR for antiplasmodial activity and falcipain-2 inhibition
Artesunate	Antimalarial activity of 4-metoxychalcones: docking studies as falcipain/plasmepsin inhibitors, ADMET and lipophilic efficiency analysis to identify a putative oral lead candidate
Atazanavir	Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function
Atovaquone	Telithromycin and quinupristin-dalfopristin induce delayed death in Plasmodium falciparum
Aza-peptide	New inhibitors of the malaria aspartyl proteases plasmepsin I and II Design, synthesis, and evaluation of aza-peptide epoxides as selective and potent inhibitors of caspases-1, -3, -6, and -8
Bicyclic amine	Starving the malaria parasite: inhibitors active against the aspartic proteases plasmepsins I, II, and IV
bisbenzylisoquinoline	High-throughput virtual screening approach of natural compounds as target inhibitors of plasmepsin-II
Bisindolylmaleimide ii	Identification of potential multitarget antimalarial drugs
Bisindolylmaleimide iii	Identification of potential multitarget antimalarial drugs
Bisindolylmaleimide x	Identification of potential multitarget antimalarial drugs
Bis-trifluoromethyl	Replacement of isobutyl by trifluoromethyl in pepstatin A selectively affects inhibition of aspartic proteinases
C(2)-symmetric compounds with a mannitol-based scaffold with either benzyloxy or allyloxy p1/p1' side chains	C2-symmetric inhibitors of Plasmodium falciparum plasmepsin II: synthesis and theoretical predictions
C2-symmetric core structure	New potent C2-symmetric malaria plasmepsin I and II inhibitors
Catestatin	Catestatin, an endogenous chromogranin A-derived peptide, inhibits in vitro growth of Plasmodium falciparum
CHEMBL113208	Multiple target-based pharmacophore design from active site structures
CHEMBL264770	Multiple target-based pharmacophore design from active site structures
CHEMBL325768	Multiple target-based pharmacophore design from active site structures
Diacylhydrazine	Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations
diamine-clamp inhibitors	Starving the malaria parasite: inhibitors active against the aspartic proteases plasmepsins I, II, and IV
Dihydroartemisinin	Antimalarial activity of 4-metoxychalcones: docking studies as falcipain/plasmepsin inhibitors, ADMET and lipophilic efficiency analysis to identify a putative oral lead candidate
Diphenylurea	Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors
Doxorubicin	Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring
E-64	New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors
E-64d	Plasmodium food vacuole plasmepsins are activated by falcipains
Ethylene diamine	Discovery of non-peptide inhibitors of Plasmepsin II by structure-based virtual screening
Extracts from xestospongia muta and plexaura homomalla	Generation of an affinity matrix useful in the purification of natural inhibitors of plasmepsin II, an antimalarial-drug target
FA12	Exploring dual inhibitory role of febrifugine analogues against Plasmodium utilizing structure-based virtual screening and molecular dynamic simulation
FA21	Exploring dual inhibitory role of febrifugine analogues against Plasmodium utilizing structure-based virtual screening and molecular dynamic simulation
Fingolimod	Potential repurposing of four FDA approved compounds with antiplasmodial activity identified through proteome scale computational drug discovery and in vitro assay
Fisetin	Dietary flavonoids fisetin and myricetin: dual inhibitors of Plasmodium falciparum falcipain-2 and plasmepsin II
formaldehyde;propyl (2S)-6-amino-2-[[(2S)-2-[4-[4-[[(1S)-1-[[(1S,2S)-4-(butylamino)-2-hydroxy-1-isobutyl-4-oxo-butyl]carbamoyl]-2-methyl-butyl]carbamoyl]phenoxy]anilino]-4-methyl-pentanoyl]amino]hexanoate	High antiplasmodial activity of novel plasmepsins I and II inhibitors
Fragment-based docking and consensus scoring, halofantrine, doxorubicin, lumefantrine	Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring
G16	Functional profiling, identification, and inhibition of plasmepsins in intraerythrocytic malaria parasites
Guanidino	Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid Design and discovery of plasmepsin II inhibitors using an automated workflow on large-scale grids
Halofantrine	Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring
Hydroxyethylamine	Discovery of non-peptide inhibitors of Plasmepsin II by structure-based virtual screening
Hydroxylethylamine	Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes High-speed optimization of inhibitors of the malarial proteases plasmepsin I and II Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II Synthesis, antimalarial evaluation and molecular modeling studies of hydroxyethylpiperazines, potential aspartyl protease inhibitors, part 2
Indinavir	Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function
Kni-10006	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II
Kni-10232	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II
Kni-10343	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II
Kni-10395	Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II
Kni-10740	Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum
Kni-10823	Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum
Knipholone	In vivo anti-malarial activity of the hydroalcoholic extract of rhizomes of Kniphofia foliosa and its constituents
Leupeptin	Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors
Ligand based virtual screening, mdg419, mdg421, mdg422, mdg425, mdg426, mdg427, mdg430, mdg432	Identification of plasmepsin inhibitors as selective anti-malarial agents using ligand based drug design
Lk1	Protease inhibitors from marine actinobacteria as a potential source for antimalarial compound
Lk2	Protease inhibitors from marine actinobacteria as a potential source for antimalarial compound
Lk3	Protease inhibitors from marine actinobacteria as a potential source for antimalarial compound
L-Lysinamide, N-[4-[4-[[[(1S,2S)-1-[[[(1S,2S)-4-(butylamino)-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]amino]carbonyl]-2-methylbutyl]amino]carbonyl]phenoxy]benzoyl]-L-leucyl-L-leucyl-N-[2-[[[[3-[trans-4-(4-chlorophenyl)cyclohexyl]-1,4-dihydro-1,4-dioxo-2-naphthalenyl]oxy]carbonyl]amino]ethyl]-N6-[(1,1-dimethylethoxy)carbonyl]-	Atovaquone-statine "double-drugs" with high antiplasmodial activity
L-Lysinamide, N-[4-[4-[[[(1S,2S)-1-[[[(1S,2S)-4-(butylamino)-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]amino]carbonyl]-2-methylbutyl]amino]carbonyl]phenoxy]benzoyl]-L-leucyl-N-[2-[[[[3-[trans-4-(4-chlorophenyl)cyclohexyl]-1,4-dihydro-1,4-dioxo-2-naphthalenyl]oxy]carbonyl]amino]ethyl]-N6-[(1,1-dimethylethoxy)carbonyl]-	Atovaquone-statine "double-drugs" with high antiplasmodial activity
L-Lysine, N-[4-[4-[[[(1S,2S)-1-[[[(1S,2S)-4-(butylamino)-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]amino]carbonyl]-2-methylbutyl]amino]carbonyl]phenoxy]benzoyl]-L-leucyl-N6-[(1,1-dimethylethoxy)carbonyl]-, propyl ester	Atovaquone-statine "double-drugs" with high antiplasmodial activity
Lopinavir	Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function
Lumefantrine	Discovery of plasmepsin inhibitors by fragment-based docking and consensus scoring
Myricetin	Dietary flavonoids fisetin and myricetin: dual inhibitors of Plasmodium falciparum falcipain-2 and plasmepsin II
N-(3–{(2-benzo[1, 3]dioxol-5-yl-ethyl)[3-(1-methyl-3-oxo-1,3-dihydro-isoindol-2-yl) propionyl]-amino}-1-benzyl-2-(hydroxyl-propyl)-4-benzyloxy-3,5dimethoxy-benzamide	Computational analysis of aspartic protease plasmepsin II complexed with EH58 inhibitor: a QM/MM MD study
N-(3-chlorophenyl)-2-sulfamoylbenzamide	Identification of Sulfamoylbenzamide derivatives as selective Cathepsin D inhibitors
N,N' -Bis(2-methyl benzimidazolyl) pentane diamideLcucl(2)	Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum Antimalarial evaluation of copper(II) nanohybrid solids: inhibition of plasmepsin II, a hemoglobin-degrading malarial aspartic protease from Plasmodium falciparum
N,N'-((2R,2'R,3S,3'S)-piperazine-1,4-diylbis(3-hydroxy-1-phenylbutane-4,2-diyl))bis(2-(1,3-dioxoisoindolin-2-yl)-3 phenylpropanamide)	Hydroxyethylamine Based Phthalimides as New Class of Plasmepsin Hits: Design, Synthesis and Antimalarial Evaluation
N,N-Diethyl-2-(5-((4′-methoxy-[1,1′-biphenyl]-4-yl)methyl)-1- (4-pentylphenyl)-1H-1,2,3-triazol-4-yl)ethan-1-amine hydrochloride	Azole-based non-peptidomimetic plasmepsin inhibitors
N,N-Diethyl-2-(5-((4′-methoxy-[1,1′-biphenyl]-4-yl)methyl)-1-pentylphenyl)-1H-1,2,3-triazol-4-yl)ethan-1-amine(4-pentylphenyl)-1H-1,2,3-triazol-4-yl)ethan-1-amine hydrochloride	Fragment Molecular Orbital Study of the Interaction between Sarco/Endoplasmic Reticulum Ca 2+-ATPase and its Inhibitor Thapsigargin toward Anti-Malarial Development
N-[(1S)-1-[[(1S,2S)-4-(butylamino)-2-hydroxy-1-isobutyl-4-oxo-butyl]carbamoyl]-2-methyl-butyl]-4-[4-[[2-[[(1S)-2-[4-[(6-methoxyquinoxalin-1-yl)amino]pentylamino]-1-methyl-2-oxo-ethyl]amino]-2-oxo-ethyl]amino]phenoxy]benzamide	High antiplasmodial activity of novel plasmepsins I and II inhibitors
N-[(1S,2S)-3-[(S)-1-((S)-1-Carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-1-(4-thiophen-3- yl-benzyloxymethyl)-propyl]-2,4,6-trifluoro-benzamide	Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II
N-[(2S)-1-{[(2S,3S)-5-{[(2S)-1-{[(2S)-1-Amino-4-methyl-1-oxo-2-pentanyl]amino}-1-oxo-2-propanyl]amino}-1-{[4-(1,3-benzodioxol-5-yl)benzyl]oxy}-3-hydroxy-5-oxo-2-pentanyl]amino}-3-methyl-1-oxo-2-butany l]-2-pyridinecarboxamideCHEMBL191130	Designing dual inhibitors against potential drug targets of Plasmodium falciparum -M17 Leucyl Aminopeptidase and Plasmepsins
N-[[4-[4-[3-(benzylamino)-3-oxo-propyl]phenyl]phenyl]methyl]-N-[2-(dibutylamino)ethyl]-4-pentyl-benzamide;methanol	Inhibitors of Plasmepsin II-potential antimalarial agents
N-[2-[[(1S)-5-amino-1-[4-[(6-methoxyquinoxalin-1-yl)amino]pentylcarbamoyl]pentyl]amino]-2-oxo-ethyl]-4-[4-[[(1S)-1-[[(1S,2S)-4-(butylamino)-2-hydroxy-1-isobutyl-4-oxo-butyl]carbamoyl]-2-methyl-butyl]carbamoyl]phenoxy]benzamide	High antiplasmodial activity of novel plasmepsins I and II inhibitors
N-[4-[[2-(dibutylamino)ethyl-(4-pentylbenzoyl)amino]methyl]phenyl]piperidine-3-carboxamide;methanol	Inhibitors of Plasmepsin II-potential antimalarial agents
N-{(1S,2S)-1-(4-Benzo[1,3]dioxol-5-yl-benzyloxymethyl)- 3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-propyl}-2,4,6-trifluoro-benzamide	Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II
N1-((2S,3R)-3-hydroxy-4-((2-(3-methoxyphenyl)propan-2-yl)amino)-1-phenylbutan-2-yl)-5-(piperidin-1-yl)-N3,N3-dipropylisophthalamide	Structures of plasmepsin II from Plasmodium falciparum in complex with two hydroxyethylamine-based inhibitors
N-acetyl-l-leucyl-l-leucyl-norleucinal	Prodomain processing of recombinant plasmepsin II and IV, the aspartic proteases of Plasmodium falciparum, is auto- and trans-catalytic
N-alkoxyamidines	Design and discovery of plasmepsin II inhibitors using an automated workflow on large-scale grids
N-alkyl chains	Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes
natural compound inhibitors	Identification of the natural compound inhibitors against Plasmodium falciparum plasmepsin-II via common feature based screening and molecular dynamics simulations
N-benzyl-2-methoxy-5-[(1E)-3-phenylbuta-1,3-dienyl]benzenesulfonamide	Antimalarial activity of 4-metoxychalcones: docking studies as falcipain/plasmepsin inhibitors, ADMET and lipophilic efficiency analysis to identify a putative oral lead candidate
Nelfinavir	Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function
Norstatines	alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases
OXO 2	2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins
OXO 3	2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins
Pepstatin a	Development of a plasmepsin II fluorescence polarization assay suitable for high throughput antimalarial drug discovery Replacement of isobutyl by trifluoromethyl in pepstatin A selectively affects inhibition of aspartic proteinases Prodomain processing of recombinant plasmepsin II and IV, the aspartic proteases of Plasmodium falciparum, is auto- and trans-catalytic Antimalarial activity of thiosemicarbazones and purine derived nitriles Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors Discovery of non-peptide inhibitors of Plasmepsin II by structure-based virtual screening
Phenoxyacetyl	Antimalarial activity enhancement in hydroxymethylcarbonyl (HMC) isostere-based dipeptidomimetics targeting malarial aspartic protease plasmepsin
Piperaquine	Inactivation of Plasmepsins 2 and 3 Sensitizes Plasmodium falciparum to the Antimalarial Drug Piperaquine
Piperidine scaffold	Discovery of non-peptide inhibitors of Plasmepsin II by structure-based virtual screening
Primaquine	High antiplasmodial activity of novel plasmepsins I and II inhibitors
propyl (2S)-2-[[(2S)-2-[4-[4-[[(1S)-1-[[(1S,2S)-4-(butylamino)-2-hydroxy-1-isobutyl-4-oxo-butyl]carbamoyl]-2-methyl-butyl]carbamoyl]phenoxy]anilino]-4-methyl-pentanoyl]amino]-6-(3,3-dimethylbutanoylamino)hexanoate	High antiplasmodial activity of novel plasmepsins I and II inhibitors
Purine	Antimalarial activity of thiosemicarbazones and purine derived nitriles
Pyridine-2-carboxylic Acid ((S)-1-{(1S,2S)-1-(4-Benzo- [1,3]dioxol-5-yl-benzyloxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-propylcarbamoyl}-2-methyl-propyl)-amide	Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II
Pyridine-2-carboxylic Acid ((S)-1-{(1S,2S)-1-(biphenyl- 3-ylmethoxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-propylcarbamoyl}-2-methyl-propyl)-amide	Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II
Pyridine-2-carboxylic Acid ((S)-1-{(1S,2S)-1-(Biphenyl- 4-ylmethoxymethyl)-3-[(S)-1-((S)-1-carbamoyl-3-methylbutylcarbamoyl)-ethylcarbamoyl]-2-hydroxy-propylcarbamoyl}-2-methyl-propyl)-amide	Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II
Pyridine-2-carboxylic Acid {(S)-1-[(1S,2S)-1-(4-Benzo- [1,3]dioxol-5-yl-benzyloxymethyl)-3-butylcarbamoyl-2- hydroxy-propylcarbamoyl]-2-methyl-propyl}-amide	Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II
Pyridine-2-carboxylic Acid {(S)-1-[(1S,2S)-1-(Biphenyl- 4-ylmethoxymethyl)-3-butylcarbamoyl-2-hydroxy-propylcarbamoyl]-2-methyl-propyl}-amide	Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II
Pyridine-2-carboxylic Acid {(S)-1-[(1S,2S)-3-[(S)-1-((S)- 1-Carbamoyl-3-methyl-butylcarbamoyl)-ethylcarbamoyl]- 2-hydroxy-1-(4-thiophen-3-yl-benzyloxymethyl)-propylcarbamoyl]-2-methyl-propyl}-amide	Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II
Pyridine-2-carboxylic Acid {(S)-1-[(1S,2S)-3-Butylcarbamoyl-2-hydroxy-1-(4-thiophen-3-yl-benzyloxymethyl)- propylcarbamoyl]-2-methyl-propyl}-amide	Design and synthesis of potent inhibitors of plasmepsin I and II: X-ray crystal structure of inhibitor in complex with plasmepsin II
Remiszewski_013	Identification of potential multitarget antimalarial drugs
Ritonavir	Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function
Rnai, dsrna	Double-stranded RNA-mediated gene silencing of cysteine proteases (falcipain-1 and -2) of Plasmodium falciparum
Ro 40-4388	Role of Plasmodium falciparum digestive vacuole plasmepsins in the specificity and antimalarial mode of action of cysteine and aspartic protease inhibitors
Saquinavir	Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function
Statine	Plasmepsin II inhibition and antiplasmodial activity of Primaquine-Statine 'double-drugs' Antimalarial drug targets in Plasmodium falciparum predicted by stage-specific metabolic network analysis Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D
Sti-571	Identification of potential multitarget antimalarial drugs
Suggested target	Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy Structural and active site analysis of plasmepsins of Plasmodium falciparum: potential anti-malarial targets
Sulfonamide 4-metychalcone	Antimalarial activity of 4-metoxychalcones: docking studies as falcipain/plasmepsin inhibitors, ADMET and lipophilic efficiency analysis to identify a putative oral lead candidate
Tcmdc-134527	Thousands of chemical starting points for antimalarial lead identification
Tcmdc-134674	Plasmepsin inhibitory activity and structure-guided optimization of a potent hydroxyethylamine-based antimalarial hit
Teriary amine	Inhibitors of Plasmepsin II-potential antimalarial agents
tert-butyl ((S)-1-(((2S,3S)-4-(4-((2S,3R)-3-((S)-2-((tert-butoxycarbonyl)amino)-4-methylpentanamido)-2-hydroxy-4-phenylbutyl)piperazin-1-yl)-3-hydroxy-1-phenylbutan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamate	Fast-Acting Small Molecules Targeting Malarial Aspartyl Proteases, Plasmepsins, Inhibit Malaria Infection at Multiple Life Stages
tert-Butyl((2R,3S)-4-([1,4'-bipiperidin]-1'-yl)-3-hydroxy-1-phenylbutan-2-yl)carbamate	Hydroxyethylamine Based Phthalimides as New Class of Plasmepsin Hits: Design, Synthesis and Antimalarial Evaluation
Tetrahydro-4-((E)-7-hydroxy-10-methoxy-6, 14-dimethyl-15-m-tolylpentadec-13-enyl) pyran-2- one	A novel compound purified from Alstonia boonei inhibits Plasmodium falciparum lactate dehydrogenase and plasmepsin II
Tetraoxane	Antimalarial activity of 4-metoxychalcones: docking studies as falcipain/plasmepsin inhibitors, ADMET and lipophilic efficiency analysis to identify a putative oral lead candidate
Thioacylals	Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents
Thiourea	Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid Design and discovery of plasmepsin II inhibitors using an automated workflow on large-scale grids
Urea	Design and discovery of plasmepsin II inhibitors using an automated workflow on large-scale grids
WR099444	New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins
WR099445	New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins
WR100080	New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins
WR100081	New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins
WR100392	New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins
WR100400	New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins
WR100484	New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins
WR101653	New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins
WR103412	New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins
X-ray of enzyme with non-peptidomimetic and achiral inhibitor	X-ray structure of plasmepsin II complexed with a potent achiral inhibitor
X-ray structures and 3d models , suggested target	Predicting functional residues in Plasmodium falciparum plasmepsins by combining sequence and structural analysis with molecular dynamics simulations
ZINC03351002	Unveiling a New Era in Malaria Therapeutics: A Tailored Molecular Approach Towards the Design of Plasmepsin IX Inhibitors

Expasy - NiceZime View
Brenda - The Comprehensive Enzyme Information System